Cargando…

Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines

Prophylactic vaccines remain the best approach for controlling the human immunodeficiency virus-1 (HIV-1) transmission. Despite the limited efficacy of the RV144 trial in Thailand, there is still no vaccine candidate that has been proven successful. Consequently, great efforts have been made to impr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chun-Wei, Saubi, Narcís, Joseph-Munné, Joan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561392/ https://www.ncbi.nlm.nih.gov/pubmed/33117367 http://dx.doi.org/10.3389/fimmu.2020.573157

Ejemplares similares

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2023)

Expression of Chimeric HPV-HIV Protein L1P18 in Pichia pastoris; Purification and Characterization of the Virus-like Particles
por: Eto, Yoshiki, et al.
Publicado: (2021)

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2022)

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1
por: Gao, Yong, et al.
Publicado: (2018)

MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice
por: Broset, Esther, et al.
Publicado: (2019)

Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2014)

Platforms, advances, and technical challenges in virus-like particles-based vaccines
por: Gupta, Reeshu, et al.
Publicado: (2023)

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
por: Saubi, Narcís, et al.
Publicado: (2020)

Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
por: Mahant, Aakash, et al.
Publicado: (2017)

Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors
por: Joseph, Joan, et al.
Publicado: (2010)

Virus like particles as a platform for cancer vaccine development
por: Ong, Hui Kian, et al.
Publicado: (2017)

Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates
por: Zhou, Fangbin, et al.
Publicado: (2023)

Newborn Mice Vaccination with BCG.HIVA(222) + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
por: Saubi, Narcís, et al.
Publicado: (2011)

Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines
por: Gomes, Ariane C., et al.
Publicado: (2017)

6-Valent Virus-Like Particle-Based Vaccine Induced Potent and Sustained Immunity Against Noroviruses in Mice
por: Hou, Wenli, et al.
Publicado: (2022)

Pre-Clinical Development of BCG.HIVA(CAT), an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2012)

Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine
por: Zhang, XiZhen, et al.
Publicado: (2011)

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Design Challenges for HIV-1 Vaccines Based on Humoral Immunity
por: Greenspan, Neil S.
Publicado: (2014)

Single Dose of Consensus Hemagglutinin-Based Virus-Like Particles Vaccine Protects Chickens against Divergent H5 Subtype Influenza Viruses
por: Wu, Peipei, et al.
Publicado: (2017)

Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates
por: Xiao, Peng, et al.
Publicado: (2021)

Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines
por: Pazos-Castro, Diego, et al.
Publicado: (2022)

Corrigendum: Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines
por: Pazos-Castro, Diego, et al.
Publicado: (2023)

A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques
por: Volkmann, Ariane, et al.
Publicado: (2022)

Mining of Marburg Virus Proteome for Designing an Epitope-Based Vaccine
por: Soltan, Mohamed A., et al.
Publicado: (2022)

Current situation in the development of a preventive HIV vaccine
por: Alcamí, José, et al.
Publicado: (2005)

Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice
por: Kurtovic, Liriye, et al.
Publicado: (2021)

The 3Ds in virus‐like particle based‐vaccines: “Design, Delivery and Dynamics”
por: Mohsen, Mona O., et al.
Publicado: (2020)

Virus-like particle vaccines with epitopes from porcine epidemic virus and transmissible gastroenteritis virus incorporated into self-assembling ADDomer platform provide clinical immune responses in piglets
por: Du, Pengfei, et al.
Publicado: (2023)

Virus-like Particles as Antiviral Vaccine: Mechanism, Design, and Application
por: Zhang, Lei, et al.
Publicado: (2023)

Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice
por: Kim, Yu-Jin, et al.
Publicado: (2017)

A Novel Neuraminidase Virus-Like Particle Vaccine Offers Protection Against Heterologous H3N2 Influenza Virus Infection in the Porcine Model
por: Pliasas, Vasilis C., et al.
Publicado: (2022)

Bacterium-Like Particles for Efficient Immune Stimulation of Existing Vaccines and New Subunit Vaccines in Mucosal Applications
por: Van Braeckel-Budimir, Natalija, et al.
Publicado: (2013)

Immunogenicity of a Virus-Like-Particle Vaccine Containing Multiple Antigenic Epitopes of Toxoplasma gondii Against Acute and Chronic Toxoplasmosis in Mice
por: Guo, Jingjing, et al.
Publicado: (2019)

Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design
por: French, Martyn A., et al.
Publicado: (2017)

Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus
por: Mobini, Saeed, et al.
Publicado: (2020)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Activation of NLRP3 Inflammasome by Virus-Like Particles of Human Polyomaviruses in Macrophages
por: Lučiūnaitė, Asta, et al.
Publicado: (2022)

Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ss7g868c37llqhqqi5hl09gar